Serum HLA-G seviyeleri ile sitokin gen polimorfizminin ilişkisi

Amaç: Bu çalışmada immünotolerojenik etkisi olduğu bilinen HLA-G molekülünün serum seviyesi ile sitokin gen polimorfizm ilişkisinin araştırılması planlanmıştır. Hasta ve Metod: İlk karaciğer nakllerini olmuş 55 hastadan alınan kan örneklerinden ayrılan serumlardan sHLA-G seviyeleri ELISA yöntemi ile ölçüldü. Araştırılan TNF-α, TGF-β, IL-10, IL-6, IFN-γ gen polimorfizmlerinin belirlenebilmesi için PCR-SSP yöntemi kullanıldı. Sonuçlar: Hastaların sitokin gen polimorfizmlerine göre serum sHLA-G seviyesi yüksek olan hasta dağılımı, TNF-alpha -308 GG %15.5, -308 G/A, A/A %20, TGF-beta kodon 10-25 T/T-G/G, T/C-G/G %16.6, kodon 10-25 T/C-G/C, C/C-G/G, T/T-G/C %16.0, IL-10 -1082 GCC/GCC %30, -1082 GCC/ACC, GCC/ATA %13, -1082 ACC/ACC, ACC/ATA, ATA/ATA %13.6, IL-6 -174 G/G,G/C %18.3, IFN-gamma +874 T/T %18.1, +874 T/A %11.7, +874 AA %15.3 olarak bulundu. Yorum: İmmün yanıtın gelişmesini ve etki yönünün belirlenmesini sağlayan sitokinler bir çok molekülün de ekspresyonunda ve sekresyonunda rol oynarlar. Sitokinlerin üretiminde etkileri olan gen polimorfizmlerinin de hastalıkların oluşmasında ve progresyonunda farklılıklara neden olduğu bilinmektedir. Çalışma sonuçlarına göre HLA-G artışına neden olan IL-10’un yüksek salınımı ile uyumlu haplotipi taşıyan hastaların %30’unda saptanan sHLA-G seviyesindeki yükseklik polimorfik yapılardan kaynaklanan bireysel farklılıklara bir örnek oluşturmaktadır.

Association between serum HLA-G levels and cytokine gene polymorphisim

Purpose: To investigate if there is an association between cytokine gene polymorphism and serum level of HLA-G, which is known to be an immunotolerogenic molecule. Patients and Methods: Fifty-five patients receiving primary liver transplants were enrolled in this study. HLA-G serum levels were determined by ELISA method. All genotyping (TNF-α, TGF-β, IL-10, IL-6, IFN-γ) experiments were performed using sequence-specific primers PCR (PCR-SSP). Results: According to the cytokine gene polymorphisms of the patients, the frequencies of high sHLA-G levels in patients were as follows: TNFalpha- 308 GG is 15.5%, -308 G/A, A/A is 20%; TGF-beta codon 10-25 T/TG/ G, T/C-G/G is 16.6%; T/C-G/C, C/C-G/G, T/T-G/C is 16.0%; IL-10-1082 GCC/GCC is 30%, -1082 GCC/ACC, GCC/ATA is 13%; ACC/ACC, ACC/ ATA, ATA/ATA is 13.6%; IL-6 -174 G/G, G/C is 18.3%; IFN-gamma +874 T/T is 18.1%, +874 T/A 11.7, +874 AA is 15.3%. Conclusion: Cytokines, which support the development of immune response and help direct its effects, also play a role in the expression and secretion of many molecules. It is known that gene polymorphisms that also affect cytokine production cause changes in the development and progression of many diseases. The results of our study demonstrated that 30% of patients who carried a haplotype compatible with high IL-10 secretion leading to HLA-G elevation had high HLA-G levels, which was an example of individual differences due to polymorphic structures.

PDF

___

1. Urosevic M., Dummer R. HLA-G - An Ace Up the Sleeve? ASHI Quarterly, Third Quarter, 2002; 106-109.
2. Carosella ED, Rouas Freiss N, Paul P, ve ark. HLA-G: A Tolerance Molecule from the Major Histocompatibility Complex. Immunol Today, 1999; 20: 60-62.
3. Carosella ED, Paul P, Moreau P, ve ark. HLA-G and –E: Fundamental and Physiopathological Aspects. Immunol Today, 2000; 21: 532-534.
4. Bainbridge D, Ellis S, Le Bouteiller P, ve ark. HLA-G remains a mystery. Trends Immunol, 2001; 22: 548-552.
5. Le Maoult, Zafaranloo K, Le Danff C, ve ark. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. The FASEB Journal, 2005; 19: 662-664.
6. Contini P, Ghio M, Poggi A. SolubleHLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol, 2003; 33: 125- 34.
7. Khalil-Daher I, Riteau B, Menier C. Role of HLA-G versus HLA-E on NK function: HLA-G is able to inhibit NK cytolysis by itself. J Reprod Immunol, 1999; 43: 175-182.
8. Le Gal FA, Riteau B, Sedlik C. HLA-G mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol, 1999; 11: 1351-1356.
9. Ellis SA, Sargent IL, Redman CW, ve ark. Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology, 1986; 59: 595-601.
10. Ober C. Immunogenetics ’98 HLA and pregnancy: The paradox of fetal allograft. Am J Hum Genet, 1998; 62: 1-5.
11. Le Bouteiller P. Solier C. Is antigen presentation the primary function of HLA-G? Microbes Infect, 2001; 3: 323-332.
12. Wiendl H, Mitsdoerffer M, Hofmeister V, ve ark. The non-classical MHC molecule HLA-G protects human muscle cells from immunemediated lysis: implications for myoblast transplantation and gene therapy. Brain, 2003; 126: 176-185.
13. Urosevic M, Kurrer M O, Kamarashev J, ve ark. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol, 2001; 159: 817.
14. Basturk B, Karakayali F, Emiroglu R, ve ark. Human Leukocyte Antigen-G, a New Parameter in the Follow-up of Liver Transplantation. Transplantation Proceedings, 2006; 38: 571-574.
15. Creput C, Le Friec G, Bahri R, ve ark. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol. 2003; 64: 1033-1038.
16. Lila N, Amrein C, Guillemain R, ve ark. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105: 1949-54.
17. Creput C, Durrbach A, Menier C, ve ark. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J. Hepatol. 2003; 4: 587-594.
18. Leigh J. Keen. The extend analysis of cytokine and receptor gene polymorphism. Transplant Immunology, 2002; 10: 143-46.
19. Akalin E, Murphy B. Gene polymorphisms and transplantation. Current Oppinion Immunology, 2001; 13: 572-76.
20. Ben-Ari Z, Mor E, Papo O, ve ark Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003; 98: 144-50.
21. Basturk B, Yavascaoglu I, Vuruskan H, ve ark. Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine. 2005; 30: 41-45.
22. Balasubramanian SP, Azmy IA, Higham SE, ve ark. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer. 2006; 14: 188.
23. Yung Y, Geraghty DE, Hunt JS. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J Reprod Immunol. 1995; 29: 179-95.
24. Chu W, Yang Y, Geraghty DE, Hunt JS. Interferons enhance HLA-G mRNA and protein in transfected mouse fibroblasts. J Reprod Immunol. 1999; 42: 1-15.
25. Basturk B, Karakayalı F, Emiroğlu R, ve ark. Human Leukocyte Antigen G; a new Parameter in the Fallow up of Liver Transplantation. Transplantation Proceedings. 2006; 38: 571-574.
26. Conti P, Kempuraj D, Kandere K, ve ark. IL-10 inflammatory/inhibitory cytokine, but not always. Immunology Letters. 2003; 86: 123-129.
27. Moreau P, Adrian-Cabestre F, Menier C, ve ark. IL-10 Selectively Induces HLA-G Expression in Human Trophoblasts and Monocytes. International Immunology. 1999; 11: 803-811.